Therapeutic management of gliosarcoma in the temozolomide era.

Abstract

Gliosarcoma (GS) is a malignant, uncommon variant of high-grade glioma comprised of infiltrative glial and atypical sarcomatous cells, identified in adult and pediatric populations. GS has been subcategorized into primary (de novo) and secondary tumors, with the latter typically arising in the setting of prior glioblastoma. Due to its rarity, the pathogenesis, epidemiology and optimal therapy of GS have been based on small retrospective cohort studies, with treatment presently utilizing regimens established for other high-grade gliomas, including combination of resection, radiotherapy and temozolomide-based chemotherapy. As more information is gathered about GS molecular profiles, novel treatment strategies may be developed to improve outcomes of GS patients. Here we summarize results of GS management with focus on the temozolomide era.

• Authors: Mary Frances McAleer, Paul D Brown
• Journal: CNS oncology (CNS Oncol) Vol. 4 Issue 3 Pg. 171-8 ( 2015) ISSN: 2045-0915 [Electronic] England
• PMID: 25905568 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents, Alkylating
• Dacarbazine
• Temozolomide

Topics

• Antineoplastic Agents, Alkylating (therapeutic use)
• Brain Neoplasms (drug therapy)
• Dacarbazine (analogs & derivatives, therapeutic use)
• Disease Management
• Gliosarcoma (drug therapy)
• Humans
• Temozolomide